title: Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide.
abstract: Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the treatment of pretreated metastatic breast cancer (mBC) based on the positive outcomes of phase II and phase III clinical trials, which enrolled mainly Western patients. Eribulin has recently been approved in an increasing number of Asian countries; however, there is limited clinical experience in using the drug in certain countries. Therefore, we established an Asian working group to provide practical guidance for eribulin use based on our clinical experience. This paper summarizes the key clinical trials, and the management recommendations for the reported adverse events (AEs) of eribulin in mBC treatment, with an emphasis on those that are relevant to Asian patients, followed by further elaboration of our eribulin clinical experience. It is anticipated that this clinical practice guide will improve the management of AEs resulting from eribulin treatment, which will ensure that patients receive the maximum treatment benefit.
authors.affiliation: Center for Breast Cancer, National Cancer Center, Goyang, Korea.
authors.forename: Jungsil
authors.initials: J
authors.lastname: Ro
authors.affiliation: Breast Cancer Center, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
authors.forename: Fiona Tsui-Fen
authors.initials: FT
authors.lastname: Cheng
authors.affiliation: Division of Medical Oncology, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.
authors.forename: Virote
authors.initials: V
authors.lastname: Sriuranpong
authors.affiliation: Department of Internal Medicine, Manila Doctor Hospital, Manila, Philippines.
authors.forename: Antonio
authors.initials: A
authors.lastname: Villalon
authors.affiliation: Division of Medical Oncology, Bombay Hospital Institute of Medical Sciences & Lilavati Hospital, Mumbai, India.
authors.forename: B K
authors.initials: BK
authors.lastname: Smruti
authors.affiliation: Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
authors.forename: Janice
authors.initials: J
authors.lastname: Tsang
authors.affiliation: Department of Medical Oncology, National Cancer Centre Singapore, Singapore.
authors.forename: Yoon Sim
authors.initials: YS
authors.lastname: Yap
keywords: Asians; Breast neoplasms; Chemotherapy; Eribulin mesylate